title: The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.
abstract: The Major histocompatibility complex (MHC) class I peptidome is thought to be generated mostly through proteasomal degradation of cellular proteins, a notion that is based on the alterations in presentation of selected peptides following proteasome inhibition. We evaluated the effects of proteasome inhibitors, epoxomicin and bortezomib, on human cultured cancer cells. Because the inhibitors did not reduce the level of presentation of the cell surface human leukocyte antigen (HLA) molecules, we followed their effects on the rates of synthesis of both HLA peptidome and proteome of the cells, using dynamic stable isotope labeling in tissue culture (dynamic-SILAC). The inhibitors reduced the rates of synthesis of most cellular proteins and HLA peptides, yet the synthesis rates of some of the proteins and HLA peptides was not decreased by the inhibitors and of some even increased. Therefore, we concluded that the inhibitors affected the production of the HLA peptidome in a complex manner, including modulation of the synthesis rates of the source proteins of the HLA peptides, in addition to their effect on their degradation. The collected data may suggest that the current reliance on proteasome inhibition may overestimate the centrality of the proteasome in the generation of the MHC peptidome. It is therefore suggested that the relative contribution of the proteasomal and nonproteasomal pathways to the production of the MHC peptidome should be revaluated in accordance with the inhibitors effects on the synthesis rates of the source proteins of the MHC peptides.
authors.affiliation: Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
authors.forename: Elena
authors.initials: E
authors.lastname: Milner
authors.forename: Lilach
authors.initials: L
authors.lastname: Gutter-Kapon
authors.forename: Michal
authors.initials: M
authors.lastname: Bassani-Strenberg
authors.forename: Eilon
authors.initials: E
authors.lastname: Barnea
authors.forename: Ilan
authors.initials: I
authors.lastname: Beer
authors.forename: Arie
authors.initials: A
authors.lastname: Admon
mesh_terms: D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D061986:MCF-7 Cells; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000494:pharmacology*; D020543:Proteome; D011719:Pyrazines / Q000494:pharmacology*
chemical_list: D001897:Boronic Acids; D015395:Histocompatibility Antigens Class I; D009842:Oligopeptides; D010455:Peptides; D061988:Proteasome Inhibitors; D020543:Proteome; D011719:Pyrazines; D000069286:Bortezomib; C078846:epoxomicin
references.citation: J Proteomics. 2010 Sep 10;73(10):1945-53
references.pmid: 20546957
references.citation: Cell Mol Life Sci. 2011 May;68(9):1553-67
references.pmid: 21390545
references.citation: Eur J Immunol. 2003 May;33(5):1250-9
references.pmid: 12731050
references.citation: Trends Cell Biol. 2011 Nov;21(11):647-55
references.pmid: 21955996
references.citation: Trends Immunol. 2011 Nov;32(11):548-58
references.pmid: 21962745
references.citation: Mol Cell Proteomics. 2002 Aug;1(8):579-91
references.pmid: 12376573
references.citation: Autoimmun Rev. 2012 Jul;11(9):627-35
references.pmid: 22100331
references.citation: J Immunol. 1998 Jul 1;161(1):83-9
references.pmid: 9647210
references.citation: J Immunol. 2001 Aug 1;167(3):1212-21
references.pmid: 11466336
references.citation: Cell Mol Life Sci. 2011 May;68(9):1543-52
references.pmid: 21387141
references.citation: Traffic. 2010 Feb;11(2):210-20
references.pmid: 19948006
references.citation: Nat Immunol. 2002 Dec;3(12):1169-76
references.pmid: 12436109
references.citation: Nature. 2003 Sep 25;425(6956):402-6
references.pmid: 14508490
references.citation: Immunol Rev. 1999 Dec;172:21-8
references.pmid: 10631934
references.citation: Nat Rev Drug Discov. 2011 Jan;10(1):29-46
references.pmid: 21151032
references.citation: Immunity. 1995 Mar;2(3):289-99
references.pmid: 7535183
references.citation: Cell Mol Life Sci. 2011 May;68(9):1533-41
references.pmid: 21390546
references.citation: Science. 1992 Mar 6;255(5049):1264-6
references.pmid: 1546329
references.citation: Cancer Res. 2008 Sep 1;68(17):6889-95
references.pmid: 18757401
references.citation: Immunogenetics. 1997;45(6):379-85
references.pmid: 9089095
references.citation: Nat Rev Immunol. 2012 Jul 13;12(8):557-69
references.pmid: 22790179
references.citation: Blood. 2005 Apr 15;105(8):3199-205
references.pmid: 15618468
references.citation: Nat Rev Immunol. 2011 Nov 11;11(12):823-36
references.pmid: 22076556
references.citation: Curr Opin Immunol. 2010 Feb;22(1):89-93
references.pmid: 20149615
references.citation: Science. 1994 Aug 26;265(5176):1234-7
references.pmid: 8066463
references.citation: Science. 1999 Feb 12;283(5404):978-81
references.pmid: 9974389
references.citation: Nat Immunol. 2010 May;11(5):449-54
references.pmid: 20364150
references.citation: Cell Mol Life Sci. 2011 May;68(9):1491-502
references.pmid: 21387144
references.citation: Science. 2000 Dec 1;290(5497):1717-21
references.pmid: 11099404
references.citation: Blood. 2012 Jun 28;119(26):e181-91
references.pmid: 22438248
references.citation: Nucleic Acids Res. 2010 Jan;38(Database issue):D736-42
references.pmid: 19906717
references.citation: Mol Cell Proteomics. 2007 May;6(5):923-38
references.pmid: 17308301
references.citation: J Immunol. 1995 Aug 15;155(4):1767-75
references.pmid: 7636233
references.citation: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18769-76
references.pmid: 20974924
references.citation: Nature. 1992 Apr 2;356(6368):443-6
references.pmid: 1557127
references.citation: Front Immunol. 2012 Mar 07;3:37
references.pmid: 22566920
references.citation: Nature. 1984 Jun 28-Jul 4;309(5971):797-9
references.pmid: 6738696
references.citation: Nat Biotechnol. 2008 Dec;26(12):1367-72
references.pmid: 19029910
references.citation: J Immunol. 2009 Nov 15;183(10):6145-50
references.pmid: 19841190
references.citation: Eur J Immunol. 2008 Mar;38(3):609-13
references.pmid: 18286570
references.citation: Nat Immunol. 2004 Jul;5(7):661-9
references.pmid: 15224091
references.citation: J Immunol. 1999 Dec 1;163(11):5851-9
references.pmid: 10570269
references.citation: Nat Rev Immunol. 2003 Dec;3(12):952-61
references.pmid: 14647477
references.citation: J Proteome Res. 2011 Apr 1;10(4):1794-805
references.pmid: 21254760
references.citation: Trends Neurosci. 2007 Jan;30(1):31-6
references.pmid: 17126920
references.citation: J Immunol Methods. 1989 May 12;119(2):203-10
references.pmid: 2470825
references.citation: Science. 1992 Mar 6;255(5049):1261-3
references.pmid: 1546328
references.citation: J Immunol. 1994 Apr 15;152(8):3884-94
references.pmid: 8144958
references.citation: J Immunol. 2009 Mar 15;182(6):3335-41
references.pmid: 19265109
references.citation: Cell. 1994 Sep 9;78(5):761-71
references.pmid: 8087844
references.citation: J Chromatogr A. 2002 Dec 6;979(1-2):233-9
references.pmid: 12498253
references.citation: Mol Cell Proteomics. 2011 Oct;10(10):O111.011833
references.pmid: 21813418
references.citation: Mol Cell Proteomics. 2003 Jun;2(6):388-98
references.pmid: 12821722
references.citation: Mol Ther. 2010 Jan;18(1):135-42
references.pmid: 19904235
references.citation: J Immunol. 2011 Feb 15;186(4):2065-72
references.pmid: 21228349
references.citation: Science. 2011 Nov 25;334(6059):1081-6
references.pmid: 22116877
references.citation: Science. 2005 Jan 28;307(5709):593-6
references.pmid: 15591165
references.citation: FASEB J. 2006 Jun;20(8):1055-63
references.pmid: 16770004
references.citation: J Immunol. 1998 Jul 1;161(1):112-21
references.pmid: 9647214
references.citation: Front Immunol. 2012 Jun 04;3:138
references.pmid: 22675326
references.citation: Nature. 1991 May 23;351(6324):290-6
references.pmid: 1709722
references.citation: Mol Cell Proteomics. 2002 May;1(5):376-86
references.pmid: 12118079
references.citation: Front Immunol. 2012 Jan 03;2:87
references.pmid: 22566876
references.citation: Cell Mol Life Sci. 2011 May;68(9):1521-32
references.pmid: 21387142
references.citation: Mol Cell Proteomics. 2006 Feb;5(2):357-65
references.pmid: 16272561
references.citation: J Immunol. 1997 Jul 15;159(2):554-64
references.pmid: 9218569
references.citation: Nature. 2011 May 19;473(7347):337-42
references.pmid: 21593866
references.citation: J Immunol. 2000 Jun 15;164(12):6147-57
references.pmid: 10843664
references.citation: Theor Biol Med Model. 2010 Jun 23;7:25
references.pmid: 20573219
references.citation: Eur J Immunol. 2002 Jan;32(1):213-22
references.pmid: 11782012
references.citation: Mol Cell Proteomics. 2012 Jan;11(1):M111.011486
references.pmid: 21969608
references.citation: Nat Immunol. 2009 May;10(5):480-7
references.pmid: 19305394